Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Trial Profile

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Axitinib (Primary) ; Bosutinib (Primary) ; Cetuximab (Primary) ; Cobimetinib (Primary) ; Crizotinib (Primary) ; Erlotinib (Primary) ; Palbociclib (Primary) ; Pertuzumab (Primary) ; Sunitinib (Primary) ; Temsirolimus (Primary) ; Trastuzumab (Primary) ; Vemurafenib (Primary) ; Vismodegib (Primary)
  • Indications Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Therapeutic Use
  • Acronyms TAPUR
  • Most Recent Events

    • 14 Aug 2017 Planned number of patients changed from 1030 to 1060.
    • 10 Jun 2017 Biomarkers information updated
    • 20 Jun 2016 Treatment arms changed from 14 to 15; with addition of Group 15 (POLE/POLD1).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top